Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00389376 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial of Silymarin for Chronic Liver Diseases
A Phase 1 study of Hepatitis C and Non-alcoholic Fatty Liver Disease, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 5
- Study locations
NCT00389376 is a Phase 1 study of Hepatitis C and Non-alcoholic Fatty Liver Disease that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 56 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT00389376, a Phase 1 study of Hepatitis C and Non-alcoholic Fatty Liver Disease, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Silymarin
Study Locations (5)
Pennsylvania
- University of Pennsylvania - Philadelphia
- Thomas Jefferson University - Philadelphia
- University of Pittsburgh, Graduate School of Public Health - Pittsburgh
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00389376
The ClinicalTrials.gov registry entry for NCT00389376 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (97% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00389376 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00389376 about?
NCT00389376 is a clinical study titled "Phase I Trial of Silymarin for Chronic Liver Diseases". The purpose of this study is to determine the safety and tolerability of different dosages of silymarin on subjects with Hepatitis C or Non-Alcoholic Fatty Liver Disease.
What is the current status of trial NCT00389376?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2006-11. Estimated completion is 2008-02.
What conditions does trial NCT00389376 study?
This clinical trial studies the following conditions: Hepatitis C, Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT00389376?
The interventions under investigation include: Placebo (DRUG), Silymarin (DRUG).
Who is sponsoring clinical trial NCT00389376?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00389376 being conducted?
This trial has 5 study locations across Massachusetts, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.